曲妥珠单抗靶向治疗HER2阳性乳腺癌的研究进展
Research Progress of Trastuzumab Targeted Therapy for HER2-Positive Breast Cancer
DOI: 10.12677/ACM.2023.1371686, PDF,   
作者: 胥世霜：延安大学第一临床医学院，陕西 延安；延安大学附属医院肿瘤科，陕西 延安
关键词: 乳腺癌；人表皮生长因子受体-2；曲妥珠单抗；靶向治疗；Breast Neoplasms； HER2； Trastuzumab； Targeted Therapy
摘要: 乳腺癌的发展趋势日益增长，其中人表皮生长因子受体2 (HER2)阳性乳腺癌占所有乳腺癌的15%~20%。HER2阳性乳腺癌侵袭性强、复发率高、预后差。随着分子生物学研究的深入，肿瘤靶向治疗的研究和临床应用取得了突破性进展，HER2靶向治疗的进展改善了HER2阳性乳腺癌患者的生存。针对HER2的单克隆抗体、酪氨酸激酶抑制剂和抗体–药物偶联物的引入显著改善了HER2阳性乳腺癌患者的预后。典型的是抗HER2抗体曲妥珠单抗，已被认为是针对HER2阳性肿瘤最有效的治疗药物之一。HER2基因在乳腺癌诊断、治疗及评价预后中具有重要指导价值。本文围绕HER2阳性乳腺癌患者的抗HER2单克隆抗体的靶向治疗做一综述。
Abstract: Breast cancer is a growing trend, with human epidermal growth factor receptor 2 (HER2) positive breast cancer accounting for 15%~20% of all breast cancers. HER2 positive breast cancer is aggres-sive, has high recurrence rate and poor prognosis. With the deepening of molecular biology re-search, the research and clinical application of tumor targeted therapy have made breakthroughs, and the progress of HER2-targeted therapy has improved the survival of patients with HER2-positive breast cancer. The introduction of monoclonal antibodies against HER2, tyrosine ki-nase inhibitors, and antibody-drug conjugates significantly improved outcomes in patients with HER2-positive breast cancer. Typical is the anti-HER2 antibody trastuzumab, which has been recog-nized as one of the most effective therapies against HER2-positive tumors. HER2 gene has important guiding value in diagnosis, treatment and prognosis evaluation of breast cancer. This review focuses on the targeted therapy of anti-HER2 monoclonal antibodies in patients with HER2 positive breast cancer.
文章引用：胥世霜. 曲妥珠单抗靶向治疗HER2阳性乳腺癌的研究进展[J]. 临床医学进展, 2023, 13(7): 12031-12037. https://doi.org/10.12677/ACM.2023.1371686

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M.S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., Bianchi, G.V., Capri, G. and de Braud, F. (2019) Resistance Mechanisms to Anti-HER2 Therapies in HER2-Positive Breast Cancer: Current Knowledge, New Research Directions and Therapeutic Perspectives. Critical Reviews in Oncology/Hematology, 139, 53-66. [Google Scholar] [CrossRef] [PubMed]
[3] Martin, M., Holmes, F.A., Ejlertsen, B., et al. (2017) Nerat-inib after Trastuzumab-Based Adjuvant Therapy in HER-2 Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double Blind, Placebo-Controlled, Phase 3 Trim. The Lancet Oncology, 18, 1688-1700. [Google Scholar] [CrossRef] 
[4] Ellis, P.A., Barrios, C.H., Eiermann, W., et al. (2015) Phase III, Randomized Study of Trastuzumab Emtansine (T -DMI) ± Pertuzumab (P) vs Trastuzumab + Taxane(HT) for First-Line Treatment of HER2-Positive MBC: Primary Results from the MARIANNE Study. Journal of Clinical On-cology, 33, 507. [Google Scholar] [CrossRef] 
[5] Cardoso, F., Kyriakides, S., Ohno, S., et al. (2019) Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Journal of Clinical Oncol-ogy, 30, 1194-220. [Google Scholar] [CrossRef] [PubMed]
[6] Cardoso, F., Senkus, E., Costa, A., et al. (2018) 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 29, 1634-1657. [Google Scholar] [CrossRef] [PubMed]
[7] Le, X.F., Pruefer, F. and Bast Jr., R.C. (2005) HER2-Targeting Antibodies Modulate the Cyclin-Dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways. Cell Cycle, 4, 87-95. [Google Scholar] [CrossRef] [PubMed]
[8] Austin, C.D., De Maziere, A.M., Pisacane, P.I., van Dijk, S.M., Eigenbrot, C., Sliwkowski, M.X., Klumperman, J. and Scheller, R.H. (2004) Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin. Molecular Biology of the Cell, 15, 5268-5282. [Google Scholar] [CrossRef] [PubMed]
[9] Collins, D.M., O’Donovan, N., McGowan, P.M., O’Sullivan, F., Duffy, M.J. and Crown, J. (2012) Trastuzumab Induces Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in HER-2-Non-Amplified Breast Cancer Cell Lines. Annals of Oncology, 23, 1788-1795. [Google Scholar] [CrossRef] [PubMed]
[10] Osoba, D., Slamon, D.J., Burchmore, M. and Murphy, M. (2002) Ef-fects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women with Metastatic Breast Cancer. Journal of Clinical Oncology, 20, 3106-3113. [Google Scholar] [CrossRef] 
[11] Xu, Y., Benlimame, N., Su, J., He, Q. and Alaoui-Jamali, M.A. (2009) Regulation of Focal Adhesion Turnover by ErbB Signalling in Invasive Breast Cancer Cells. British Journal of Cancer, 100, 633-643. [Google Scholar] [CrossRef] [PubMed]
[12] Petit, A.M., Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B. and Kerbel, R.S. (1997) Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2/neu Receptor Tyrosine Kinases Downregulate Vascular Endothelial Growth Factor Production by Tumor Cells in Vitro and in Vivo: Angiogenic Implications for Signal Transduction Therapy of Solid Tumors. Am. J. Pathol, 151, 1523-1530.
[13] Sorace, A.G., Quarles, C.C., Whisenant, J.G., Hanker, A.B., McIntyre, J.O., Sanchez, V.M. and Yankeelov, T.E. (2016) Trastuzumab Improves Tumor Perfusion and Vascular Delivery of Cytotoxic Therapy in a Murine Model of HER2+ Breast Cancer: Preliminary Results. Breast Cancer Research and Treatment, 155, 273-284. [Google Scholar] [CrossRef] [PubMed]
[14] 王慧, 赵安帝, 杨谨. 曲妥珠单抗联合帕妥珠单抗用于HER2阳性早期乳腺癌研究进展[J]. 华中科技大学学报(医学版), 2020, 49(1): 111-116.
[15] 韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2阳性乳腺癌的靶向治疗研究进展[J]. 中华普通外科学文献(电子版), 2021, 15(6): 453-458.
[16] Wang, Q., Zhang, X., Shen, E., Gao, J., Cao, F., Wang, X., Li, Y., Tian, T., Wang, J., Chen, Z., Wang, J. and Shen, L. (2016) The Anti-HER3 Antibody in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2- Positive Gastric Cancer. Cancer Letters, 380, 20-30. [Google Scholar] [CrossRef] [PubMed]
[17] Slamon, D.J., et al. (1989) Studies of the HER-2/neu Protoonco-gene in Human Breast and Ovarian Cancer. Science, 244, 707-712. [Google Scholar] [CrossRef] [PubMed]
[18] Wolff, A.C., et al. (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 31, 3997-4013. [Google Scholar] [CrossRef] 
[19] Rimawi, M.F., Schiff, R. and Osborne, C.K. (2015) Targeting HER2 for the Treatment of Breast Cancer. Annual Review of Medicine, 66, 111-128. [Google Scholar] [CrossRef] [PubMed]
[20] Moasser, M.M. (2007) The Oncogene HER2: Its Sig-naling and Transforming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. [Google Scholar] [CrossRef] [PubMed]
[21] Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C.K., Rimawi, M.F. and Schiff, R. (2020) Towards Personalized Treatment for Early Stage HER2-Positive Breast Cancer. Nature Reviews Clinical Oncology, 17, 233-250. [Google Scholar] [CrossRef] [PubMed]
[22] Clynes, R.A., Towers, T.L., Presta, L.G. and Ravetch, J.V. (2000) Inhibitory Fc Receptors Modulate in Vivo Cytotoxicity against Tumor Targets. Nature Medicine, 6, 443-446. [Google Scholar] [CrossRef] [PubMed]
[23] Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C.K., Rimawi, M.F. and Schiff, R. (2020) Towards Personalized Treatment for Early Stage HER2-Positive Breast Cancer. Nature Reviews Clinical Oncology, 17, 233-250. [Google Scholar] [CrossRef] [PubMed]
[24] Scheuer, W., et al. (2009) Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models. Cancer Research, 69, 9330-9336. [Google Scholar] [CrossRef] 
[25] Yamashita-Kashima, Y., et al. (2011) Pertuzumab in Com-bination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models. Clinical Cancer Research, 17, 5060- 5070. [Google Scholar] [CrossRef] 
[26] Gianni, L., et al. (2012) Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-Label, Phase 2 Trial. The Lancet Oncology, 13, 25-32. [Google Scholar] [CrossRef] 
[27] Llombart-Cussac, A., et al. (2017) HER2-Enriched Subtype as a Predictor of Pathological Complete Response Following Trastuzumab and Lapatinib without Chemotherapy in Ear-ly-Stage HER2-Positive Breast Cancer (PAMELA): an Open-Label, Single-Group, Multicentre, Phase 2 Trial. The Lan-cet Oncology, 18, 545–554. [Google Scholar] [CrossRef] 
[28] Rimawi, M.F., et al. (2013) Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab with Hormonal Therapy and without Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 31, 1726-1731. [Google Scholar] [CrossRef] 
[29] Untch, M., Rezai, M., Loibl, S., et al. (2010) Neoad-juvant Treatment with Trastuzumab in HER2-Positive Breast Cancer: Results from the GeparQuattro Study. Journal of Clinical Oncology, 28, 2024-2031. [Google Scholar] [CrossRef] 
[30] Gianni, L., Eiermann, W., Semiglazov, V., et al. (2010) Neoadju-vant Chemotherapy with Trastuzumab Followed by Adjuvant Trastuzumab versus Neoadjuvant Chemotherapy Alone, in Patients with her2positive Locally Advanced Breast Cancer (the NOAH trial): A Randomised Controlled Superiority Tri-al with a Parallel HER2negative Cohort. The Lancet, 375, 377-384. [Google Scholar] [CrossRef] 
[31] Cameron, D., et al. (2017) 11 Years’ Follow-Up of Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer: Final Analysis of the HERceptin Ad-juvant (HERA) Trial. The Lancet, 389, 1195-1205. [Google Scholar] [CrossRef] 
[32] Perez, E.A., et al. (2014) Trastuzumab Plus Adjuvant Chem-otherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 32, 3744-3752. [Google Scholar] [CrossRef] 
[33] Swain, S.M., et al. (2015) Pertuzumab, Trastuzumab and Docet-axel in HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine, 372, 724-734. [Google Scholar] [CrossRef] 
[34] Hurvitz, S.A., Martin, M., Symmans, W.F., et al. (2018) Neoadju-vant Trastuzumab, Pertuzumab and Chemotherapy versus Trastuzumab Emtansine Plus Pertuzumab in Patients with HER-2-Positive Breast Cancer (KRISTINE): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet On-cology, 19, 115-126. [Google Scholar] [CrossRef] 
[35] Gallagher, C.M., More, K., Masaquel, A., et al. (2016) Sur-vival in Patients with Non-Metastatic Breast Cancer Treated with Adjuvant Trastuzumab in Clinical Practice. Springer-plus, 5, Article No. 395. [Google Scholar] [CrossRef] [PubMed]
[36] Ali, S., Hendry, J., Le, D., Mondal, P.K., Sami, A., Chalchal, H., Haider, K., Ahmed, O., El-Gayed, A., Wright, P., Pauls, M., Johnson, K. and Ahmed, S. (2022) Efficacy of Adjuvant Trastuzumab in Women with HER2-Positive T1a or bN0M0 Breast Cancer: A Population-Based Cohort Study. Scientific Reports, 12, Article No. 1068. [Google Scholar] [CrossRef] [PubMed]
[37] Piccart-Gebhart, M., Holmes, E., Baselga, J., et al. (2016) Adju-vant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2positive Breast Cancer: Results from the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Journal of Clinical Oncology, 34, 1034-1042. [Google Scholar] [CrossRef] 
[38] Slamon, D.J., Leyland-jones, B., Shak, S., et al. (2001) Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2. The New England Journal of Medicine, 344, 783-792. [Google Scholar] [CrossRef] 
[39] Marty, M., Cognetti, F., Maraninchi, D., et al. (2005) Ran-domized Phase Iitrial of the Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients with Human Epi-dermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: The M77001 Study Group. Journal of Clinical Oncology, 23, 4265-4274. [Google Scholar] [CrossRef] 
[40] Giordano, S.H., Temin, S., Kirshner, J.J., et al. (2014) Systemic Therapy for Patients with Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American So-ciety of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 32, 2078-2099. [Google Scholar] [CrossRef] 
[41] Bachelot, T., Ciruelos, E., Schneeweiss, A., et al. (2019) Prelimi-nary Safety and Efficacy of First-Line Pertuzumab Combined with Trastuzumab and Taxane Therapy for HER2-Positive Locally Recurrent or Metastatic Breast Cancer (PERUSE). Annals of Oncology, 30, 766-773. [Google Scholar] [CrossRef] [PubMed]
[42] Robert, N., Leyland-jones, B., Asmar, L., et al. (2006) Randomized Phase III Study of Trastuzumab, Paclitaxel and Carboplatin Compared with Trastuzumab and Paclitaxel in Women with HER-2-Overexpressing Metastatic Breast Cancer. Annals of Oncology, 24, 2786-2792. [Google Scholar] [CrossRef] 

为你推荐